LeonaBio Gets $20 Price Target Ahead of June Pipeline Test
Piper Sandler initiated coverage of LeonaBio with an overweight rating and a $20 price target. Shares rose 1.45% to $9.81 on volume just over 51,000. LeonaBio will present ALS drug ATH-1105 on June 3 and join an oncology trials panel June 24. Phase 3 enrollment for breast cancer drug lasofoxifene is expected to finish in late 2026.